### Agenda Topics

**Noon**

#### Welcome and Introductions:
- Sara Salek, MD, Chief Medical Officer, AHCCCS
- 8-16-16 P&T Minutes Review and Vote

#### AHCCCS and BH Drug Lists

**Supplemental Rebate Class Review:**

1. **Inhaled Antibiotics**
   - Clinical review: Sarah Martinez: Provider Synergies
   - Pharma Testimony: None
   - Public Testimony: None

2. **Cytokine and CAM Antagonists**
   - Clinical review: Sarah Martinez: Provider Synergies
   - Pharma Testimony:
     - Michelle Mui: Cimzia-UCB
     - Scott Budsberg: Enbrel-Amgen
     - Laura Hill: Humira-Abbvie
     - Marlies Ozias: Orencia-BMS
     - Carrie Johnson: Oteza-Celgene
     - Rick Smith: Xeljanz-Pfizer
   - Public Testimony: None

3. **Epinephrine – Self Injected**
   - Clinical review: Sarah Martinez: Provider Synergies
   - Pharma Testimony:
     - Roger Stephens: EpiPen-Mylan
   - Public Testimony: None

4. **Growth Hormone**
   - Clinical review: Sarah Martinez: Provider Synergies
   - Pharma Testimony:
     - Patrick Archer: Genotropin-Pfizer
     - Jignesh Patel: Norditropin-Novonordisk
   - Public Testimony: None

5. **Long-Acting Narcotic Analgesics**
   - Clinical review: Sarah Martinez: Provider Synergies
   - Pharma Testimony:
     - Jerod Downing: Butrans-Purdue Pharma
     - Laurence Ikeda: Embeda-Pfizer
     - Jerod Downing: Hysingla ER- Purdue Pharma
     - Jerod Downing: Oxycontin-Purdue Pharma
   - Public Testimony:
     - Matthew Rhodes: Arrowhead Health Centers
<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Item</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>**New Drug Reviews: Non-Supplemental Rebate Class: ** <em>Suzi Berman, AHCCCS</em></td>
</tr>
<tr>
<td>3:00PM</td>
<td>- Xiidra - Lifitegrast ophthalmic solution</td>
</tr>
<tr>
<td></td>
<td>- Zynbryta - Daclizumab</td>
</tr>
<tr>
<td></td>
<td>- Ocaliva - Obeticholic acid</td>
</tr>
<tr>
<td></td>
<td>- Briviact - Brivaracetam</td>
</tr>
<tr>
<td>3:10PM</td>
<td>**Follow up on HIV Subcommittee: ** <em>Suzi Berman, AHCCCS</em></td>
</tr>
<tr>
<td></td>
<td>a) HIV Therapeutic Class and Single Agent Reviews</td>
</tr>
<tr>
<td></td>
<td>b) Genvoya PA status</td>
</tr>
<tr>
<td></td>
<td>**Follow up Oral Oncology Subcommittee: ** <em>Suzi Berman, AHCCCS</em></td>
</tr>
<tr>
<td>3:30PM</td>
<td>**Opioid 7-day Quantity Limitation - ** <em>Shana Malone, AHCCCS</em></td>
</tr>
<tr>
<td>4:00PM</td>
<td>**Pill Splitting: ** <em>Dr. Chakmakian, CMO, United Health Care</em></td>
</tr>
<tr>
<td>4:30PM</td>
<td><strong>Agenda Items for the January 25, 2017 P&amp;T:</strong></td>
</tr>
<tr>
<td></td>
<td>The Inhaled Glucocorticoids Drug class will be reviewed at the next P&amp;T Committee.</td>
</tr>
<tr>
<td>4:55PM</td>
<td><strong>Meeting Adjourned</strong></td>
</tr>
</tbody>
</table>

**2017 Meeting Dates:**
Monday, Thursday, April 13, 2017, Tuesday, July 18, 2017, & Thursday, October 12, 2017